InvestorsContact Us
    Resources

    News &
    Insights

    The latest from Oral Biolife—science, progress, and perspectives on the future of bone regeneration.

    Why We Built Oral BioLife
    Blog
    FeaturedBlog

    Why We Built Oral BioLife

    The story behind Oral BioLife began with a simple observation: bone heals mechanically, yet every therapy on the market works chemically. We set out to change that.

    6 min
    Read article
    OBL delivers Piezoelectric Regeneration: A New Frontier in Bone Regeneration
    Blog

    OBL delivers Piezoelectric Regeneration: A New Frontier in Bone Regeneration

    Jan 31, 2026
    The Science of Piezoelectric Bone Regeneration
    Blog

    The Science of Piezoelectric Bone Regeneration

    Piezoelectricity in bone has been studied for decades. Oral BioLife is the first to harness it clinically. Here's how the science works—and why it matters

    8 min
    From Veterinary to Human: The Restoris™ Story
    Blog

    From Veterinary to Human: The Restoris™ Story

    Our veterinary product Restoris™ launched in Q4 2025. Here's why starting in animal health was a strategic decision—and what it means for our human programs.

    4 min
    What "First-in-Class" Means for Oral BioLife
    Blog

    What "First-in-Class" Means for Oral BioLife

    Oral BioLife is building a first-in-class piezoelectric regenerative platform. Here's what that designation means—and why it matters for investors, partners, and patients.

    5 min
    Why Periodontal Disease Is a $30 Billion Unsolved Problem
    Blog

    Why Periodontal Disease Is a $30 Billion Unsolved Problem

    Over one billion people worldwide suffer from periodontal disease. The bone loss it causes has no predictable, non-surgical solution—until now.

    5 min
    Oral BioLife Announces First-in-Human Clinical Trial of Ambrilux™ Dental Gel for Periodontal Bone Regeneration
    Press

    Oral BioLife Announces First-in-Human Clinical Trial of Ambrilux™ Dental Gel for Periodontal Bone Regeneration

    Breakthrough piezoelectric therapy enters clinical development, targeting the $30 billion periodontal disease market

    Media Kit

    Everything you need to tell the OBL story—logos, brand guidelines, images, and leadership bios.

    media@oralbiolife.compress@oralbiolife.com